Next Article in Journal
Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma
Next Article in Special Issue
PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy
Previous Article in Journal
The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma
Previous Article in Special Issue
Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma
Review

Positron Emission Tomography Imaging of Macrophages in Cancer

Departments of Chemistry and Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Tadashi Watabe and Frederik Lars Giesel
Cancers 2021, 13(8), 1921; https://doi.org/10.3390/cancers13081921
Received: 22 March 2021 / Revised: 13 April 2021 / Accepted: 13 April 2021 / Published: 16 April 2021
(This article belongs to the Special Issue Molecular Imaging and Radio-Nuclide Therapy in Cancers)
Tumor-associated macrophages (TAMs) play numerous roles in cancer biology and are an important component of the relationship between immune system response and tumor progression. Several new immunotherapy techniques have been developed that target TAMs and are under investigation in both clinical and preclinical settings. Despite this surge of new immunotherapy techniques, a means to specifically and quantifiably measure the presence of TAMs to ensure the viability of these therapies, has yet to be widely investigated. The development of molecular imaging agents that target TAMs provides a path to noninvasively gain valuable insight into the molecular and functional characteristics of the tumor microenvironment and how the immune response facilitates the progression of cancer or therapy response. This article reviews published preclinical and clinical research in the imaging of TAMs through Positron Emission Tomography (PET).
Macrophages are large phagocytic cells that can be classified as a type of white blood cell and may be either mobile or stationary in tissues. The presence of macrophages in essentially every major disease makes them attractive candidates to serve as therapeutic targets and diagnostic biomarkers. Macrophages that are found in the microenvironment of solid tumors are referred to as tumor-associated macrophages (TAMs) and have been shown to influence chemoresistance, immune regulation, tumor initiation and tumor growth. The imaging of TAMs through Positron Emission Tomography (PET) has the potential to provide valuable information on cancer biology, tumor progression, and response to therapy. This review will highlight the versatility of macrophage imaging in cancer through the use of PET. View Full-Text
Keywords: PET; imaging biomarkers; radiotracers; macrophages; TAMs PET; imaging biomarkers; radiotracers; macrophages; TAMs
Show Figures

Figure 1

MDPI and ACS Style

Parker, C.C.; Lapi, S.E. Positron Emission Tomography Imaging of Macrophages in Cancer. Cancers 2021, 13, 1921. https://doi.org/10.3390/cancers13081921

AMA Style

Parker CC, Lapi SE. Positron Emission Tomography Imaging of Macrophages in Cancer. Cancers. 2021; 13(8):1921. https://doi.org/10.3390/cancers13081921

Chicago/Turabian Style

Parker, Candace C., and Suzanne E. Lapi 2021. "Positron Emission Tomography Imaging of Macrophages in Cancer" Cancers 13, no. 8: 1921. https://doi.org/10.3390/cancers13081921

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop